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Abstract
Background: Hip fracture is associated with high mortality. Cardiovascular disease and other comorbidities
requiring long-term anticoagulant medication are common in these mostly elderly patients. The objective of our
observational cohort study of patients undergoing surgery for hip fracture was to study the association between
preoperative use of low-dose acetylsalicylic acid (LdAA) and intraoperative blood loss, blood transfusion and first-
year all-cause mortality.
Methods: An observational cohort study was conducted on patients with hip fracture (cervical requiring
hemiarthroplasty or pertrochanteric or subtrochanteric requiring internal fixation) participating in a randomized trial
that found lack of efficacy of a compression bandage in reducing postoperative bleeding. The participants were
255 patients (≥50 years) of whom 118 (46%) were using LdAA (defined as ≤320 mg daily) preoperatively. Bleeding
variables in patients with and without LdAA treatment at time of fracture were measured and blood transfusions
given were compared using logistic regression. The association between first-year mortality and preoperative use
of LdAA was analyzed with Cox regression adjusting for age, sex, type of fracture, baseline renal dysfunction and
baseline cardiovascular and/or cerebrovascular disease.
Results: Blood transfusions were given postoperatively to 74 (62.7%) LdAA-treated and 76 (54%) non-treated
patients; the adjusted odds ratio was 1.8 (95% CI 1.04 to 3.3). First-year mortality was significantly higher in LdAA-
treated patients; the adjusted hazard ratio (HR) was 2.35 (95% CI 1.23 to 4.49). The mortality was also higher with
baseline cardiovascular and/or cerebrovascular disease, adjusted HR 2.78 (95% CI 1.31 to 5.88). Patients treated with
LdAA preoperatively were significantly more likely to suffer thromboembolic events (5.7% vs. 0.7%, P = 0.03).
Conclusions: In patients with hip fracture (cervical treated with hemiarthroplasty or pertrochanteric or
subtrochanteric treated with internal fixation) preoperative use of low-dose acetylsalicylic acid was associated with
significantly increased need for postoperative blood transfusions and significantly higher all-cause mortality during
one year after surgery.
Background
Hip fracture is common in elderly people and these
patients have a more than doubled mortality risk com-
pared to that of an age-matched non-fracture population
[1]. Large studies have reported 30-day mortality of 6%
to 11% and a 90-day mortality of up to 20% [2,3]. The
causes of the high mortality are not fully known and
although comorbidities, including cardiovascular disease,
have been suggested to at least partly explain the
increased mortality, other factors may be involved [4,5].
Since antiplatelet drugs and anticoagulants are increas-
ingly used for primary and secondary prevention in car-
diovascular disease, a large proportion of patients
admitted for hip fracture are on such treatment, mainly
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any medium, provided the original work is properly cited.low-dose acetylsalicylic acid (LdAA). Recent studies have
recommended the continuation over surgery for many
of these agents with the exception of warfarin and other
vitamin K antagonists [6-8]. The rationale for not dis-
continuing LdAA prior to emergency fracture surgery is
its irreversible inhibition of platelet function for the pla-
telets’ entire life span (8 to 10 days). However, possible
association between preoperative anti-platelet therapy,
specifically LdAA, and mortality following hip fracture
has not previously been ascertained. We performed a
randomized controlled trial to assess the efficacy of a
pneumatic compression bandage, applied to the hip
immediately after hip fracture surgery, in reducing the
need for blood transfusion and found that the bandage
did not reduce the proportion of transfused patients or
the amount of transfusion [9]. In this observational
study of the trial participants we analyzed intraoperative
blood loss, transfusions, postoperative complications and
first-year all-cause mortality after surgery. Our hypoth-
esis was that patients using LdAA before the hip frac-
ture had higher need for blood transfusions and higher
first-year mortality than those not using LdAA at the
time of hip fracture.
Methods
The original randomized trial has been described in
detail elsewhere [9]. The aim of the trial was to evalu-
ate the efficacy if a pneumatic compression bandage
applied over the hip after surgery for a hip fracture.
Briefly, patients with a proximal femoral fracture pre-
senting at the Emergency Department of Kristianstad
Hospital, Sweden, January 2005 through December
2006, were screened by an orthopedic surgeon for
enrollment in the trial. The inclusion criteria were
patients 50 years or older with cervical fractures
planned for hemiarthroplasty or pertrochanteric or
subtrochanteric fractures planned for internal fixation
with plate and gliding screw or twin hook or with
proximal intramedullary nail. The exclusion criteria
were non-displaced subcapital (intracapsular) cervical
fracture planned for internal fixation, pathologic frac-
ture due to malignancy, concomitant fractures or inju-
ries that might require blood transfusion, and patients
refusing blood transfusion. Patients were randomly
assigned to the compression group (n = 136) or non-
compression group (n = 152) immediately after sur-
gery. The results of the trial showed that the compres-
sion bandage did not have any effect on bleeding or
blood transfusion requirements. For the present report
focusing on preoperative use of LdAA, patients from
both arms of the original trial were combined as we
did not anticipate that thec o m p r e s s i o nb a n d a g eh a d
any bearing on the results.
Treatment
According to clinical practice prophylaxis against perio-
perative bleeding was given to all patients with an intra-
venous injection of tranexamic acid (100 mg/kg body
weight) 20 minutes preoperatively and a second injec-
tion after 4 hours. Prophylactic treatment against
thromboembolic events was given to all patients with a
subcutaneous injection of 40 mg enoxaparin daily for at
least 10 days after surgery. The transfusion threshold
used was blood hemoglobin (Hb) below 100 g/L.
Patients on LdAA (defined as 320 mg daily or lower),
dipyridamol or clopidogrel continued with the medica-
tion, but patients on warfarin had their medication with-
drawn on admission and were managed according to
vitamin K antagonist reversing strategy.
Assessments
At baseline, preoperative use of medication with antith-
rombotic effect, including warfarin, acetylsalicylic acid
or other anti-platelet drugs, and non-steroidal anti-
inflammatory drugs (NSAIDs), were recorded. At admis-
sion, Hb, platelet count, international normalized ratio
(INR), activated partial thromboplastin time (APTT),
and serum creatinine, were measured. The examining
physician obtained medical history and recorded the
presence or absence of specific conditions on a preo-
perative standardized protocol; heart disease (without
further specification), hypertension, diabetes, lung dis-
ease (specified as asthma, chronic bronchitis or other
pulmonary disease), rheumatoid arthritis, and other ser-
ious disease. These diagnoses were then verified through
review of patients’ records by one investigator (AK) who
also documented the presence of cardiovascular disease,
cerebrovascular disease or both. Before surgery, the
anesthesiologist classified the patients according to the
American Society of Anesthesiologists (ASA) score.
Intraoperative blood loss was estimated by the nurse
anesthetist according to standard procedures. The num-
ber of red cell units transfused before, during and after
surgery (up to discharge from hospital or death) was
recorded. Complications up to 3 months after surgery
were recorded. First-year deaths from any cause and the
date of death were retrieved from the hospital adminis-
trative database linked to the National Board of Health
and Welfare’s Cause of Death Register.
Sample size
The pretrial sample size estimation was based on the
original trial’s two transfusion-related primary outcome
measures [9]. As a measure of precision in this analysis
we present 95% confidence intervals for the differences
in bleeding and transfusion-related variables and
mortality.
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The study was approved by the Medical Research Ethics
Committee of Lund University (704/2004-11-30).
Informed consent was obtained from all participating
patients or, for patients who could not provide consent
themselves due to cognitive impairment, from a family
member.
Statistical analysis
Baseline characteristics of the patients using and those
not using LdAA preoperatively were compared with the
t-test for continuous variables and Fisher’s exact test for
proportions. Bleeding and transfusion-related variables
were compared between the two groups using logistic
regression or analysis of covariance (ANCOVA) adjust-
ing for age (as continuous variable), sex, baseline Hb
and type of surgery and odds ratios and 95% confidence
intervals (CI) were calculated. A Kaplan-Meier survival
curve was constructed to compare first-year mortality
among patients according to preoperative use of LdAA.
The Fisher exact test was used to compare mortality
according to patient sex and dose of preoperative LdAA.
The Fisher exact test was also used to compare post-
operative complications in LdAA users and non-users.
A Cox regression analysis was performed with first-year
mortality as the dependent variable. The independent
variables were age, sex, LdAA at the time of fracture,
type of fracture, baseline cardiovascular and/or cerebro-
vascular disease and renal dysfunction. The hazard ratio
(HR) with 95% CI was calculated. Because patients with
hypertension were classified as having a cardiovascular
disease and the ASA score (I, II or III/IV) was essen-
tially based on cardiovascular disease we did not include
these two variables in the model. To investigate whether
a relationship between preoperative use of LdAA and
mortality may differ between women and men we
repeated the Cox regression analysis adding a term for
the interaction between sex and preoperative LdAA use
to the model. Adding compression use as a covariate in
the models did not change the results. All analyses were
t w o - s i d e da n daPv a l u e<0 . 0 5w a sc o n s i d e r e dt oi n d i -
cate statistical significance.
Results
Patients
During the study period 555 consecutive patients with
potentially eligible hip fracture were registered at the
emergency department. Of 333 patients assessed for
eligibility by the orthopedic surgeon on duty at the
Emergency Department, 288 patients were included in
the original randomized trial (14 did not meet the inclu-
sion criteria, 9 refused to participate, 4 had a refracture
and 18 were excluded for other reasons). Of the 222
patients not assessed for eligibility (mean age 83 years),
70% were women, and 51% had a cervical and 49% a
pertrochanteric or a subtrochanteric fracture.
The number of patients excluded from our present ana-
lysis was 33; patients receiving warfarin (n = 24) and
patients receiving high-dose acetylsalicylic acid, dipyrida-
mol or clopidogrel (n = 9). Of the 255 trial participants eli-
gible for this analysis, 118 (46.3%) used LdAA (50 mg in 1
patient, 75 mg in 68 patients, 150 mg in 2 patients, 160
mg in 40 patients, 250 mg in 2 patients and 320 mg in 5
patients). Patients using LdAA preoperatively were older
and more likely to have hypertension, cardiovascular and/
or cerebrovascular disease, renal dysfunction and ASA
score of III or IV than patients not using LdAA (Table 1).
Bleeding and Transfusion
Patients using LdAA at the time of fracture had signifi-
cantly higher APTT and INR values and were signifi-
cantly more likely to receive postoperative blood
transfusion (odds ratio 1.8), but did not differ signifi-
cantly from patients not using LdAA regarding the pro-
portion transfused or the amount of blood transfusions
given before and during surgery (Table 2).
Mortality
At 30 days after surgery 17 patients (6.7%) had died, 14
were preoperative LdAA users and 3 were non-users
(11.9% versus 2.2%). The 90-day mortality was 10.6%
and first-year mortality was 19.2%, both higher among
preoperative LdAA users (17.8% vs. 4.4% and 29.7% vs.
10.2% respectively) (Figure 1). Among the preoperative
LdAA users the type of surgery was hemiarthroplasty in
14 of the 35 1-year non-survivors (40%) and in 37 of the
83 survivors (45%). Among the preoperative LdAA
users, 1-year mortality was 31.7% (26 of 82) in women
and 25% (9 of 36) in men (P = 0.52) and among non-
users it was 9.3% (10 of 108) in women and 13.8% (4 of
29) in men (P = 0.50). Among the LdAA users treated
with ≤75 mg, 1-year mortality was 30.4% (21 of 69
patients) and among those treated with ≥150 mg it was
28.6% (14 of 49 patients) (P = 1.0).
In the Cox regression analysis use of LdAA preopera-
tively was associated with significantly higher first-year
mortality, with an adjusted HR of 2.35 (Table 3). In the
Cox regression model that included a term for the inter-
action between sex and preoperative LdAA use, the sex-
specific HR was estimated to be 2.88 for women and
1.25 for men. However, this difference in effect of LdAA
was shown not to be statistically significant when tested
using a likelihood-ratio test (P = 0.25).
Early postoperative complications
The total number of patients who suffered postoperative
complications up to three months after the fracture did
not differ between LdAA users and non-users (Table 4).
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c a n t l ym o r el i k e l yt ob ea f f l i c t e dw i t ht h r o m b o e m b o l i c
events, such as deep vein thrombosis and pulmonary
embolism (5.7% vs. 0.7%, P = 0.03). Among LdAA users
those who did not survive one year the number of
patients with complications were 22 (63%) compared to
the survivors 32 (39%).
Discussion
The principal findings of our study were significantly
higher need for blood transfusion postoperatively and
higher first-year mortality in patients using LdAA before
major hip surgery. The mortality risk in the preoperative
LdAA users compared to non-users was increased
nearly five times during the first month after hip frac-
ture and was thereafter threefold higher up to one year
after fracture.
Prophylactic treatment with LdAA for cardiovascular
disease, both primary and secondary, is common in
older people. An Irish study in 2006 showed that 42% of
hip fracture patients were regular users of acetylsalicylic
acid before the fracture [10]. Similarly, 46% of the
patients in our study used LdAA, which can be com-
pared to 17% of the whole population 80 years or older
in Sweden during 2006 (according to the Swedish Pre-
scription Drug Register).
At the time of our study national guidelines regarding
prophylactic use of acetylsalicylic acid for cardiovascular
disease recommended dosages between 75 mg to 320
mg but recent international recommendations have pro-
posed a dose of 75 mg for most indications [11]. This
can be of importance as most side effects of acetylsa-
licylic acid are dose-related and differences in effects on
bleeding time and fibrinogenic activity have been shown
with doses of 75 mg and 160 mg [12]. However, we did
not find any significant difference in 1-year mortality
between patients treated with ≤75 mg LdAA compared
to those treated with ≥150 mg. Since acetylsalicylic acid
in the blood is 50 to 80 percent protein-bound, metabo-
lized for the most part in the liver and excreted mainly
by the kidneys, the amount of active drug depends
mainly on renal function and concomitant drug use
[13]. Also, sex-related difference in excretion of acetylsa-
licylic acid has been shown, with women more likely to
have higher drug concentrations in the blood [14].
Although the effect of preoperative use of LdAA on 1-
year mortality in our study was higher in women than
in men the difference was not statistically significant.
This question may need to be investigated in a larger
sample. Additionally, due to age-related decline in kid-
ney function, higher concentrations of free salicylate can
lead to increased risk of bleeding [15,16].
Preoperative discontinuati o no fL d A Ai nh i pf r a c t u r e
patients is not an option as surgery should be done
without unnecessary delay [17]. In doses of 75 to 160
mg irreversible blockade of cyclooxygenase lasts through
the platelets’ life span of 8 to 10 days. Because cardiac
disease is common in hip fracture patients, withdrawal
of LdAA for a few days may also increase the risk of
cardiovascular complications[13]. Rebound phenomena
connected to promotion of prothrombogenic factors is
also a risk factor for thromboembolic complications
which in itself makes withdrawal questionable [13].
In our original randomized trial we did not include
patients with cervical fractures treated with internal
Table 1 Characteristics of the patients according to
preoperative use of low-dose acetylsalicylic acid (LdAA)
LdAA No
LdAA
P
value
(n =
118)
(n =
137)
Age, mean (SD) 84.0
(7.6)
80.8
(9.5)
< 0.01
Women, n (%) 82 (69.5) 108
(78.8)
0.11
Institutional residence, n (%) 29 (24.6) 31 (22.6) 0.77
Type of surgery (fracture), n (%) 0.07
Hemiarthroplasty (cervical) 51 (43.2) 43 (31.4)
*
Fixation (subtrochanteric or
pertrochanteric)
67 (56.8) 94 (68.6)
Time from admission to surgery (hrs)
†,
mean (SD)
20.1
(10.7)
19.2
(9.3)
0.51
Type of anesthesia, n (%)
Spinal 113
(95.8)
136
(99.3)
0.1
General 5 (4.2) 1 (0.7) 0.1
NSAID medication at fracture, n (%) 6 (5.1) 8 (5.8) 1.00
Medical history, n (%)
Cardiovascular disease 72 (61) 56 (41) < 0.01
Cerebrovascular disease 16 (13.6) 3 (2.2) < 0.01
Hypertension 46 (39) 33 (24.1) 0.01
Diabetes 17 (14.4) 12 (8.8) 0.17
Renal dysfunction (serum creatinine)‡ 31 (26.3) 15 (11.0) < 0.01
Pulmonary disease 8 (6.8) 15 (10.9) 0.28
Rheumatoid arthritis 2 (1.7) 8 (5.8) 0.11
Other disease 2 (1.7) 2 (1.5) 1.00
ASA score n (%) 0.02
I 7 (5.9) 15 (10.9)
II 54 (45.8) 81 (59.1)
III 52 (44.1) 38 (27.7)
IV 5 (4.2) 3 (2.2)
Compression bandage, n (%) 55 (47) 59 (43) 0.61
*Including 1 total arthroplasty
† No data available for 15 patients receiving and 10 patients not receiving
acetylsalicylic acid
‡ Defined as creatinine ≥105 μmol/L in males and ≥95 μmol/L in females
ASA: American Society of Anesthesiologists; NSAID: non-steroidal anti-
inflammatory drugs.
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dure than hemiarthroplasty and usually not requiring
blood transfusion. This group of patients usually
includes both younger healthier patients and very old
frail persons with limited walking ability or with an
expected short life span. Because the three surgical pro-
cedures used in this study are major procedures that
may differ in the amount of related blood loss we chose
Table 2 Bleeding and transfusion-related data of the patients according to preoperative use of low-dose acetylsalicylic
acid (LdAA)
LdAA No LdAA Mean difference or odds ratio (95% CI) * P value
(n = 118) (n = 137)
Hemoglobin (g/L) at baseline 126 (15.8) 124 (14.2) 0.16
Platelet count (×10
9/L) 264 (125) 263 (90) 0.97
APTT 33.1 (5.9) 31.6 (4.1) 0.02
INR 1.07 (0.12) 1.04 (0.09) 0.01
Patients transfused pre- or intraoperatively 47 (39.8) 49 (35.8) 1.5 (0.78, 2.8) 0.23
Units transfused pre- or intraoperatively 0.7 (0.9) 0.7 (1.0) 0.1 (-0.1, 0.3) 0.27
Bleeding intraoperatively (mL) 363 (235) 316 (329) 45 (-27, 117) 0.22
Patients transfused postoperatively 74 (62.7) 76 (54) 1.8 (1.04, 3.3) 0.04
Units transfused postoperatively 1.3 (1.3) 1.1 (1.2) 0.3 (-0.01, 0.62) 0.06
Hemoglobin day 1 (g/L) 109 (11.1) 108 (10.4) 0.3 (-2.4, 3.0) 0.89
Hemoglobin day 5 (g/L)
† 111 (10.7) 113 (9.5) -1.9 (-4.5, 0.77) 0.11
Values are shown as mean (SD) except patients transfused shown as n (%)
*Logistic regression or ANCOVA adjusting for age, sex, baseline hemoglobin and type of surgery.
† No data were available for 7 patients using and 5 patients not using acetylsalicylic acid
APTT: activated partial thromboplastin time; INR: international normalized ratio
Figure 1 Kaplan-Meier survival estimates during first year after surgery for hip fracture according to preoperative use of low-dose
acetylsalicylic acid (LdAA), analysis time is number of days since surgery.
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sis of bleeding and transfusion outcomes. However,
using type of fracture in the analysis gave essentially
similar results both in the original study and in this ana-
lysis (data not shown).
Both surgical and medical management of patients
with hip fracture have improved during the last decade,
but mortality has not decreased as might have been
expected [3]. Despite that several studies have shown
high mortality following hip fracture few studies have
involved interventions to decrease it. The most fre-
quently proposed solution has been to focus on fall pre-
vention and not on interventions to diminish
postoperative mortality. Doubts about the effectiveness
of fall prevention on long-term mortality have been
raised in a study comparing all-cause mortality in hip
fracture patients with that of a general population [18].
Fields that need to be further studied include bleeding
complications, blood transfusi o n s ,n u t r i t i o n ,c o n g e s t i v e
heart failure, hydration, chest infections, pharmaceutical
treatment, cognitive function, and frailty.
Early mortality (within 120 days) following hip frac-
ture has been shown to be related to patient age and
sex, type of fracture, pre-fracture residence, mobility and
ASA score [4,5,19]. A possible factor behind the higher
mortality in the LdAA treated patients is the increased
need for postoperative red blood cell transfusion.
Patients treated with LdAA have increased bleeding dia-
thesis and, in our study, they also had somewhat higher
APTT and INR values, the reason for which is unclear
because these values are not expected to be affected by
LdAA. Although the differences are statistically signifi-
cant, the numeric differences are small and their clinical
relevance is uncertain. Other studies have shown up to
20 percent increase in blood loss in acetylsalicylic acid
treated patients, but no significant increase in mortality
[10,20]. Although some studies have shown doubled
amount of bleeding complications in LdAA treated
patients, the clinical significance of these complications
has been disputed. Blood transfusions have been shown
to both cause and to worsen congestive heart failure
through circulatory overload and by causing fever, low
blood pressure and pulmonary symptoms [10,21-23].
Studies showing significant increase in mortality in
patients receiving transfusions have, however, mainly
been carried out on patients in critical care units and
not specifically on orthopaedic patients [23,24]. The 100
g/L hemoglobin level used as threshold for transfusion
in our study may be considered to be relatively high.
However, some previous studies have used a similar
threshold although others have used a threshold as low
as 85 g/L [20]. The indication for red cell transfusions
should ideally be identified individually for each patient
instead of a set pretransfusion threshold and be based
on premorbidity and relevant clinical risk.
One reason for the higher mortality among the preo-
perative LdAA users may be the higher risk of early
postoperative complications often leading to longer time
before start of mobilization and rehabilitation [25].
Although postoperative complications were few there
was a significantly higher incidence of thromboembolic
events among LdAA users than among non-users. The
number of patients afflicted with these complications
was small but considering that LdAA treated patients
had higher APTT and INR values and increased bleed-
ing diathesis this seemingly paradoxical finding, merits
further study. Even so it accentuates the need for a risk-
benefit analysis when considering the use of antiplatelet
therapy in frail elderly patients.
Previous studies of hip fracture patients have also
shown an effect of preoperative LdAA on postoperative
blood transfusion. Manning et al. studied 89 patients
with femoral neck fractures treated with hemiarthro-
plasty or dynamic hip screw fixation with regard to the
effect of preoperative aspirin on blood loss and
Table 3 First-year mortality hazard ratios for baseline
factors including preoperative use of low-dose
acetylsalicylic acid (LdAA) in a Cox regression
Factors Hazard
ratio
95% CI P
value
Preoperative LdAA use 2.35 1.23 - 4.49 0.01
Age at fracture (per year) 1.08 1.03 - 1.13 < 0.01
Sex (men vs women) 0.85 0.44 - 1.63 0.62
Fracture type (cervical vs
subtrochanteric
or pertrochanteric
0.92 0.52 - 1.63 0.77
Cardiovascular or cerebrovascular
disease
2.78 1.32 - 5.88 0.01
Renal dysfunction* 1.04 0.54 - 2.00 0.91
*Defined as creatinine ≥105 umol/L in males and ≥95 umol/L in females
Table 4 Early postoperative complications according to
preoperative use of low-dose acetylsalicylic acid (LdAA)
Events LdAA No LdAA P value
(n = 118) (n = 137)
Cardiovascular 8 (6.8) 5 (3.6) 0.26
Cerebrovascular 2 (1.7) 0 (0) 0.13
Thromboembolic 6 (5.1) 1 (0.7) 0.03
Pulmonary infection 12 (10.2) 8 (5.8) 0.20
Lower urinary tract infection 23 (19.5) 25 (18.2) 0.80
Wound related 7 (5.9) 9 (6.6) 0.83
Reoperation 1 (0.8) 2 (1.5) 0.65
Other serious * 2 (1.7) 7 (5.1) 0.14
Any complication 54 (45.8) 48 (35.0) 0.08
* Kidney failure, gastrointestinal bleeding, septicemia (unknown origin), ileus,
multiorgan failure, deep pressure ulcer.
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showed no significant effect on perioperative blood loss,
the 24 LdAA treated patients included in the analysis
were significantly more likely to receive postoperative
blood transfusion than the 52 patients without LdAA, a
finding similar to our study, which also similarly did not
show differences in intraoperative blood loss.
Some of the strengths of our study are that it included
a representative sample of patients above 50 years with
hip fracture, excluding only those with non-displaced
cervical fracture treated with pin fixation (as those
patients seldom require blood transfusion), that the
majority of patients were operated within 24 hours after
admission, and that we followed all participants pro-
spectively for up to one year after surgery.
The main limitation of our study is that its primary
objective was to evaluate the efficacy of a compression
bandage in reducing need for blood transfusion and the
mortality analysis is thus secondary. In the initial trial
the proportion of LdAA treated patients in the two
groups (compression vs non-compression) was similar
and the compression bandage did not show any effects
on postoperative blood transfusions or hemoglobin. We
therefore assumed that the intervention with compres-
sion bandage did not influence the results of the present
report. This is supported by the finding that adding
postoperative use of compression bandage as a covariate
to the analyses did not change the results. Another pos-
sible limitation is the large number of patients not
assessed for eligibility for participation in the original
trial by the orthopedic surgeon at the emergency room.
Possible reasons for not assessing patients are that the
surgeon did not know about the trial, had assessed the
patients to be ineligible but failed to document this or
was unwilling to recruit patients because of the extra
work involved. However, these patients had similar char-
acteristics to the patients included in the present report
and since we have described the exact inclusion criteria
for the trial we believe the patients in this study are
representative of patients fulfilling these criteria.
Increased first-year mortality was seen both in patients
using LdAA before fracture and in those with baseline
cardiovascular and/or cerebrovascular comorbidity, with
the latter having larger effect. The exact causes of the
increased mortality among LdAA users are not known
but this study does not exclude the possibility of side
effects from acetylsalisylic acid as a contributing factor.
In a US study of 8930 patients with hip fracture it was
shown that pulmonary complications were as common
as cardiac complications in causing early mortality [27].
In our study only data on all-cause mortality were ana-
lyzed since we lacked information on cause of death.
Finally, more detailed information on other medications
used by the patients before surgery could have facilitated
a more comprehensive assessment of the patients’ risk
of bleeding.
Conclusions
In patients with hip fracture (cervical treated with hemi-
arthroplasty or trochanteric treated with internal fixa-
tion) preoperative use of LdAA was associated with
significantly increased need for postoperative blood
transfusions and significantly higher all-cause mortality
during one year after surgery.
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